therapy

It’s still cannabis earnings season, but we’re also turning to look at some of the news from the psychedelics industry. This Trade To Black Podcast, Shadd Dales, Anthony Varrell, and Benjamin A. Smith take a more granular look at Cresco Labs, Columbia Care, and the news about COMPASS...

Nick Watchorn had suffered for most of his adult life from severe post-traumatic stress disorder (PTSD) before he sought psychedelic treatments to deal with his chronic condition. He credits those psychoactive sessions, and particularly the work he did afterwards in a process known as integration...

Socrates Rosenfeld, CEO and co-founder of Jane Technologies In the last week of August, the remaining U.S. troops flew out of Afghanistan ending two decades of war. Over that period of time, between 1.9 to 3 million U.S. service members served in Afghanistan and Iraq, with over half of them...

By Rodney Wallace, former pro soccer player and founder of CBD brand Rewind. At first, I was skeptical about sharing my thoughts and giving my opinion on “the Simone Biles  Saga”. The word saga in itself makes it seem as if pulling out of a major Olympic event due to personal...

Digital health and therapeutics will play a crucial role in the future of medicine. Across medical and mental health industries, companies are realizing that the confluence of healthcare and digital platforms will be part of the future of medicine. Digital therapeutics seem to be especially...

According to a new poll conducted by Hill-HarrisX, 65% of registered voters say psychedelic substances do not have medical use. That’s far more than psychedelic legalization advocates would like, but far less than I would’ve expected. Given nearly 50 years of anti-psychedelics...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Ehave, Inc. (OTCMKTS:EHVVF) is a provider of digital therapeutics, delivering evidence-based therapeutic interventions to patients. ...

Capricor Therapeutics Inc.’s (NASDAQ: CAPR) shares soared after data that pointed to a 100 percent survival rate in critical COVID-19 patients treated with new CAP-1002 cardiac cell therapy was released. What Happened Six critically ill COVID-19 patients were treated with CAP-1002, a new...